Receive The Newest Study Notifications

Pfizer Completes Acquisition of Therachon: Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio

by Lance Smith | Jul 1, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470...

Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model

by Lance Smith | Jul 1, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Data Supports Therapeutic Role of GKT831 in Advanced Liver Fibrosis Results published in Clinics and Research in Hepatology and Gastroenterology Phase 3 trial being planned in primary biliary cholangitis  ARCHAMPS, France, July 01, 2019 (GLOBE NEWSWIRE) —...

Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis

by Lance Smith | Jul 1, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Data show crisaborole ointment, 2%, a steroid-free topical treatment, was well-tolerated over 4-week treatment period Safety profile consistent with previous clinical trial experience Pfizer Inc. (PFE) today announced top-line results from a Phase 4 study (CrisADe...

Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

by Lance Smith | Jul 1, 2019 | Study Scavenger Clinical Trial Recruitment Platform

First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history of peanut allergy Antigen-agnostic approach could potentially be used to address multiple food allergies Vedanta...

Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia

by Lance Smith | Jul 1, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that the first patient has been...

Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

by Lance Smith | Jul 1, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Phase I results provide additional clinical activity data for Bicycles Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the successful completion of...